Castle Biosciences appoints Kimberlee Caple and Ellen Goldberg to board

CASTLE BIOSCIENCES INC

Appointed Kimberlee Caple as Class III director (term until 2022 annual meeting).
Appointed Ellen Goldberg as Class I director (term until 2023 annual meeting).
Each receives $40,000 annual cash, 5,365 stock options, and 1,320 RSUs per standard policy.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Kimberlee Caple

Class III Director

CSTL · CASTLE BIOSCIENCES INC

Effective: 2021-07-14
Filed: July 16, 2021, 7:59 PM ET

the Board appointed (i) Kimberlee Caple to serve as a Class III director until the Company’s 2022 annual meeting of stockholders

Appointed

Ellen Goldberg

Class I Director

CSTL · CASTLE BIOSCIENCES INC

Effective: 2021-07-14
Filed: July 16, 2021, 7:59 PM ET

and (ii) Ellen Goldberg to serve as a Class I director until the Company’s 2023 annual meeting of stockholders

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Kimberlee Caple was appointed as Class III Director at CASTLE BIOSCIENCES INC.

Action: appointed
Role: Class III Director

Exact text from the filing

the Board appointed (i) Kimberlee Caple to serve as a Class III director until the Company’s 2022 annual meeting of stockholders

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Ellen Goldberg was appointed as Class I Director at CASTLE BIOSCIENCES INC.

Action: appointed
Role: Class I Director

Exact text from the filing

and (ii) Ellen Goldberg to serve as a Class I director until the Company’s 2023 annual meeting of stockholders

View on SEC.gov

CASTLE BIOSCIENCES INC filing history →

Source: SEC EDGAR

accession 0001447362-21-000166

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.